Hematopoietic Growth Factor support in the Elderly treated with Chemotherapy

Area of Science:

• Oncology
• Geriatrics
• Hematology

Background:

• The majority of cancer patients are over 65, with projections indicating a rise to 70% post-2030.
• Elderly patients frequently present with comorbidities, polypharmacy, and functional decline, complicating cancer treatment.
• Geriatric assessment is crucial for optimizing therapeutic decisions in older adults undergoing cancer therapy.

Purpose of the Study:

• To evaluate the role of prophylactic granulocyte-colony stimulating factor (G-CSF) and erythropoietin in managing chemotherapy-induced complications in elderly cancer patients.
• To explore the impact of anemia and neutropenia on the quality of life (QOL) in this demographic.
• To assess the feasibility of home-based administration of pegfilgrastim and erythropoietin for elderly patients with limited access to specialized care.

Main Methods:

• Review of clinical conditions influencing chemotherapy efficacy and tolerability in elderly patients.
• Analysis of the prophylactic use of G-CSF to mitigate severe neutropenia and febrile neutropenia.
• Examination of anemia in the elderly, its association with chronic disease, and resistance to erythropoietin.

Main Results:

• Prophylactic G-CSF significantly reduces the incidence and duration of severe neutropenia and febrile episodes.
• Anemia is prevalent in elderly cancer patients, exacerbated by inflammation and contributing to reduced QOL.
• Home administration of pegfilgrastim and erythropoietin may be a viable option for frail elderly patients.

Conclusions:

• Targeted interventions like G-CSF and erythropoietin can improve chemotherapy outcomes and QOL in elderly cancer patients.
• Further research is needed to compare the cost-effectiveness of biosimilars versus originator long-acting treatments in diverse healthcare systems.